- Home
- PRCT vs VKTX Comparison
PRCT vs VKTX Comparison
Compare PRCT & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRCT
- VKTX
- Stock Information
- Founded
- PRCT 2009
- VKTX 2012
- Country
- PRCT United States
- VKTX United States
- Employees
- PRCT N/A
- VKTX N/A
- Industry
- PRCT Medical Specialities
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- PRCT Health Care
- VKTX Health Care
- Exchange
- PRCT Nasdaq
- VKTX Nasdaq
- Market Cap
- PRCT 2.9B
- VKTX 3.4B
- IPO Year
- PRCT 2021
- VKTX 2015
- Fundamental
- Price
- PRCT $53.03
- VKTX $23.94
- Analyst Decision
- PRCT Strong Buy
- VKTX Strong Buy
- Analyst Count
- PRCT 7
- VKTX 12
- Target Price
- PRCT $91.43
- VKTX $89.75
- AVG Volume (30 Days)
- PRCT 1.0M
- VKTX 4.5M
- Earning Date
- PRCT 04-24-2025
- VKTX 04-23-2025
- Dividend Yield
- PRCT N/A
- VKTX N/A
- EPS Growth
- PRCT N/A
- VKTX N/A
- EPS
- PRCT N/A
- VKTX N/A
- Revenue
- PRCT $224,498,000.00
- VKTX N/A
- Revenue This Year
- PRCT $46.28
- VKTX N/A
- Revenue Next Year
- PRCT $32.67
- VKTX N/A
- P/E Ratio
- PRCT N/A
- VKTX N/A
- Revenue Growth
- PRCT 64.84
- VKTX N/A
- 52 Week Low
- PRCT $47.04
- VKTX $18.92
- 52 Week High
- PRCT $103.81
- VKTX $81.86
- Technical
- Relative Strength Index (RSI)
- PRCT 42.69
- VKTX 46.06
- Support Level
- PRCT $51.27
- VKTX $18.92
- Resistance Level
- PRCT $54.75
- VKTX $27.09
- Average True Range (ATR)
- PRCT 3.64
- VKTX 2.31
- MACD
- PRCT 0.19
- VKTX 0.26
- Stochastic Oscillator
- PRCT 49.48
- VKTX 61.44
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.